End Of An Era As Galapagos CEO Van De Stolpe Retires
Founded Belgian Biotech In 1999
Some 22 years after founding what was one of the biggest success stories in Europe's biotech sector before a recent series of setbacks in the clinic struck, Onno van de Stolpe has decided to retire as Galapagos CEO and the search has already started for his successor.
You may also be interested in...
Lead Toledo compound GLPG3970 has failed to live up to expectations in three clinical studies, setting Galapagos's pipeline plans back and causing further concern among the investment community.
The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."
Following a trio of high-profile setbacks, the Belgian biotech is looking to fill the gap between the European launches of its rheumatoid arthritis drug Jyseleca and its programs back in Phase II via in-licensing and M&A.